Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...

Its strategic focus encompasses diverse therapeutic areas, such as oncology and cardiovascular disease ... generated $460 ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen's Immunology, Oncology, and Cardiology Portfolio Drives Its Wide Moat Amgen has its roots in providing supportive-care products to kidney disease and cancer patients, but the firm has ...

Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular ... next-generation products, Aranesp and ...

Its strategic focus encompasses diverse therapeutic areas, such as oncology and cardiovascular disease ... for the quarter (up 3%). These products underscore Amgen's capacity to seize growth ...